U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07199959) titled 'Study on the Mechanism of Acquired Resistance of Entrectinib' on Nov. 12, 2024.
Brief Summary: The goal of this observational study is to learn about the mechanism of acquired resistance in first line trearment of ROS1-positive NSCLC with entrectinib. The main question it aims to answer is:
what is the acquired resistant mechanism of entrectinib as first line treatment setting in patients?
Tissue or blood samples of participants who have already taken entrectinib as their regular medical care for NSCLC will send for Next gene sequencing for genomic profiles and bioinformatic analysis.
Study Start Date: Jan. 15
Study Type: OBSERVA...